Genetics of Neurofibromatosis 1-Associated Peripheral Nerve Sheath Tumors

References

• Newsham I., Hadjistilianou T., Cavenee W. K. Retinoblastoma. The Metabolic & Molecular Bases of Inherited Disease8th Ed., C. R. Scriver, A. L. Beaudet, W. S. Sly, D. Valle. McGraw-Hill, New York 2001; Vol. 1: 819–848
   Google Scholar
• Muller A., Fishel R. Mismatch repair and the hereditary non-polyposis colorectal cancer syndrome (HNPCC). Cancer Investig. 2002; 20: 102–109
   PubMed Web of Science ®Google Scholar
• Bodmer W. Familial adenomatous polyposis (FAP) and its gene, APC. Cytogenet. Cell Genet. 1999; 86: 99–104
   PubMedGoogle Scholar
• Lengauer C., Kinzler K. W., Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396: 643–649
   PubMed Web of Science ®Google Scholar
• Korf B. R. Plexiform neurofibromas. Am. J. Med. Genet. 1999; 89: 31–37
   PubMed Web of Science ®Google Scholar
• Sorensen S. A., Mulvihill J. J., Nielsen A. Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N. Engl. J. Med. 1986; 314: 1010–1015
   PubMed Web of Science ®Google Scholar
• Poyhonen M., Niemela S., Herva R. Risk of malignancy and death in neurofibromatosis. Arch. Pathol. Lab. Med. 1997; 121: 139–143
   PubMed Web of Science ®Google Scholar
• Rasmussen S. A., Yang Q., Friedman J. M. Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am. J. Hum. Genet. 2001; 68: 1110–1118
   PubMed Web of Science ®Google Scholar
• Evans D. G., Baser M. E., McGaughran J., Sharif S., Howard E., Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J. Med. Genet. 2002; 39: 311–314
   PubMed Web of Science ®Google Scholar
• Huson S. M., Compston D. A., Clark P., Harper P. S. A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J. Med. Genet. 1989; 26: 704–711
   PubMed Web of Science ®Google Scholar
• Ducatman B. S., Scheithauer B. W., Piepgras D. G., Reiman H. M., Ilstrup D. M. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986; 57: 2006–2021
   PubMed Web of Science ®Google Scholar
• Korf B. R. Diagnosis and management of neurofibromatosis type 1. Curr. Neurol. Neurosci. Rep. 2001; 1: 162–167
   PubMedGoogle Scholar
• Friedman J. M., Riccardi V. M. Clinical and epidemiological features. Neurofibromatosis. Phenotype, Natural History, and Pathogenesis3rd Ed., J. M. Friedman, D. H. Gutmann, M. MacCollin, V. M. Riccardi. The Johns Hopkins University Press, Baltimore 1999; Vol. 1: 29–86
   Google Scholar
• North K. Neurofibromatosis type 1. Am. J. Med. Genet. 2000; 97: 119–127
   PubMed Web of Science ®Google Scholar
• Gutmann D. H., Aylsworth A., Carey J. C., Korf B., Marks J., Pyeritz R. E., Rubenstein A., Viskochil D. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. Jama 1997; 278: 51–57
   PubMed Web of Science ®Google Scholar
• Lakkis M. M., Tennekoon G. I. Neurofibromatosis type 1. I. General overview. J. Neurosci. Res. 2000; 62: 755–763
   PubMed Web of Science ®Google Scholar
• Li Y., O'Connell P., Breidenbach H. H., Cawthon R., Stevens J., Xu G., Neil S., Robertson M., White R., Viskochil D. Genomic organization of the neurofibromatosis 1 gene (NF1). Genomics 1995; 25: 9–18
   PubMed Web of Science ®Google Scholar
• Marchuk D. A., Saulino A. M., Tavakkol R., Swaroop M., Wallace M. R., Andersen L. B., Mitchell A. L., Gutmann D. H., Boguski M., Collins F. S. cDna cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics 1991; 11: 931–940
   PubMed Web of Science ®Google Scholar
• Wallace M. R., Marchuk D. A., Andersen L. B., Letcher R., Odeh H. M., Saulino A. M., Fountain J. W., Brereton A., Nicholson J., Mitchell A. L., Brownstein B. H., Collins F. S. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients 1749]. Science 1990; 249: 181–186
   PubMed Web of Science ®Google Scholar
• Viskochil D., Buchberg A. M., Xu G., Cawthon R. M., Stevens J., Wolff R. K., Culver M., Carey J. C., Copeland N. G., Jenkins N. A., White R., O'Connell P. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 1990; 62: 187–192
   PubMed Web of Science ®Google Scholar
• Cawthon R. M., Weiss R., Xu G. F., Viskochil D., Culver M., Stevens J., Robertson M., Dunn D., Gesteland R., O'Connell P., White R. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 1990; 62: 193–201
   PubMed Web of Science ®Google Scholar
• Daston M. M., Scrable H., Nordlund M., Sturbaum A. K., Nissen L. M., Ratner N. The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes. Neuron 1992; 8: 415–428
   PubMed Web of Science ®Google Scholar
• Huynh D. P., Lin C. T., Pulst S. M. Expression of neurofibromin, the neurofibromatosis 1 gene product: studies in human neuroblastoma cells and rat brain. Neurosci. Lett. 1992; 143: 233–236
   PubMed Web of Science ®Google Scholar
• Buchberg A. M., Cleveland L. S., Jenkins N. A., Copeland N. G. Sequence homology shared by neurofibromatosis type-1 gene and IRA-1 and IRA-2 negative regulators of the RAS cyclic AMP pathway. Nature 1990; 347: 291–294
   PubMed Web of Science ®Google Scholar
• Xu G. F., O'Connell P., Viskochil D., Cawthon R., Robertson M., Culver M., Dunn D., Stevens J., Gesteland R., White R., Weiss R. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 1990; 62: 599–608
   PubMed Web of Science ®Google Scholar
• McCormick F. ras GTPase activating protein: signal transmitter and signal terminator. Cell 1989; 56: 5–8
   PubMed Web of Science ®Google Scholar
• Klose A., Ahmadian M. R., Schuelke M., Scheffzek K., Hoffmeyer S., Gewies A., Schmitz F., Kaufmann D., Peters H., Wittinghofer A., Nurnberg P. Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1. Hum. Mol. Genet. 1998; 7: 1261–1268
   PubMed Web of Science ®Google Scholar
• Zhang Y. Y., Vik T. A., Ryder J. W., Srour E. F., Jacks T., Shannon K., Clapp D. W. Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. J. Exp. Med. 1998; 187: 1893–1902
   PubMed Web of Science ®Google Scholar
• The NF1 gene as a tumor suppressor in neurofibromatosis type 1, L. D. Side, K. M. Shannon. Bios Scientific Publishers, Oxford 1998
   Google Scholar
• Cichowski K., Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell 2001; 104: 593–604
   PubMed Web of Science ®Google Scholar
• Zhu Y., Parada L. F. Neurofibromin, a tumor suppressor in the nervous system. Exp. Cell Res. 2001; 264: 19–28
   PubMed Web of Science ®Google Scholar
• Gutmann D. H. The neurofibromatoses: when less is more. Hum. Mol. Genet. 2001; 10: 747–755
   PubMed Web of Science ®Google Scholar
• Weiss B., Bollag G., Shannon K. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. Am. J. Med. Genet. 1999; 89: 14–22
   PubMed Web of Science ®Google Scholar
• Serra E., Ars E., Ravella A., Sanchez A., Puig S., Rosenbaum T., Estivill X., Lazaro C. Somatic NF1 mutational spectrum in benign neurofibromas: mRNA splice defects are common among point mutations. Hum. Genet. 2001; 108: 416–429
   PubMed Web of Science ®Google Scholar
• Messiaen L. M., Callens T., Mortier G., Beysen D., Vandenbroucke I., Van Roy N., Speleman F., Paepe A. D. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Human Mutat. 2000; 15: 541–555
   PubMed Web of Science ®Google Scholar
• Fahsold R., Hoffmeyer S., Mischung C., Gille C., Ehlers C., Kucukceylan N., Abdel-Nour M., Gewies A., Peters H., Kaufmann D., Buske A., Tinschert S., Nurnberg P. Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain. Am. J. Hum. Genet. 2000; 66: 790–818
   PubMed Web of Science ®Google Scholar
• Kayes L. M., Riccardi V. M., Burke W., Bennett R. L., Stephens K. Large de novo DNA deletion in a patient with sporadic neurofibromatosis 1, mental retardation, and dysmorphism. J. Med. Genet. 1992; 29: 686–690
   PubMed Web of Science ®Google Scholar
• Kayes L. M., Burke W., Riccardi V. M., Bennett R., Ehrlich P., Rubenstein A., Stephens K. Deletions spanning the neurofibromatosis 1 gene: identification and phenotype of five patients. Am. J. Hum. Genet. 1994; 54: 424–436
   PubMed Web of Science ®Google Scholar
• Kluwe L., Friedrich R. E., Korf B., Fahsold R., Mautner V. F. NF1 mutations in neurofibromatosis 1 patients with plexiform neurofibromas. Human Mutat. 2002; 19: 309
   PubMedGoogle Scholar
• Kaufmann D., Muller R., Bartelt B., Wolf M., Kunzi-Rapp K., Hanemann C. O., Fahsold R., Hein C., Vogel W., Assum G. Spinal neurofibromatosis without cafe-au-lait macules in two families with null mutations of the NF1 gene. Am. J. Hum. Genet. 2001; 69: 1395–1400
   PubMed Web of Science ®Google Scholar
• Side L., Taylor B., Cayouette M., Conner E., Thompson P., Luce M., Shannon K. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N. Engl. J. Med. 1997; 336: 1713–1720
   PubMed Web of Science ®Google Scholar
• Lott I. T., Richardson E. P., Jr. Neuropathological findings and the biology of neurofibromatosis. Adv. Neurol. 1981; 29: 23–32
   PubMedGoogle Scholar
• Woodruff J. M. Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis. Am. J. Med. Genet. 1999; 89: 23–30
   PubMed Web of Science ®Google Scholar
• Huson S. M. Neurofibromatosis 1: a clinical and genetic overview. The Neurofibromatoses: A Pathogenetic and Clinical Overview1st Ed., S. M. Huson, R. A.C. Hughes. Chapman and Hall Medical, London 1994; 160–203
   Google Scholar
• Waggoner D. J., Towbin J., Gottesman G., Gutmann D. H. Clinic-based study of plexiform neurofibromas in neurofibromatosis 1. Am. J. Med. Genet. 2000; 92: 132–135
   PubMed Web of Science ®Google Scholar
• Riccardi V. M. Neurofibromatosis, Phenotype, Natural History, Pathogenesis. The Johns Hopkins University Press, Batimore 1992
   Google Scholar
• Huson S. M., Harper P. S., Compston D. A. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain 1988; 111(Pt 6)1355–1381
   PubMed Web of Science ®Google Scholar
• Ferner R. E., Gutmann D. H. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res. 2002; 62: 1573–1577
   PubMed Web of Science ®Google Scholar
• Molenaar W. M., Dijkhuizen T., van Echten J., Hoekstra H. J., van den Berg E. Cytogenetic support for early malignant change in a diffuse neurofibroma not associated with neurofibromatosis. Cancer Genet. Cytogenet. 1997; 97: 70–72
   PubMed Web of Science ®Google Scholar
• Leroy K., Dumas V., Martin-Garcia N., Falzone M. C., Voisin M. C., Wechsler J., Revuz J., Creange A., Levy E., Lantieri L., Zeller J., Wolkenstein P. Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: a clinicopathologic and molecular study of 17 patients. Arch. Dermatol. 2001; 137: 908–913
   Google Scholar
• Watanabe T., Oda Y., Tamiya S., Masuda K., Tsuneyoshi M. Malignant peripheral nerve sheath tumour arising within neurofibroma. An immunohistochemical analysis in the comparison between benign and malignant components. J. Clin. Pathol. 2001; 54: 631–636
   PubMed Web of Science ®Google Scholar
• Tischfield J. A. Loss of heterozygosity or: how I learned to stop worrying and love mitotic recombination. Am. J. Hum. Genet. 1997; 61: 995
   PubMedGoogle Scholar
• Fearon E. R. Human cancer syndromes: clues to the origin and nature of cancer. Science 1997; 278: 1043–1050
   PubMed Web of Science ®Google Scholar
• Colman S. D., Williams C. A., Wallace M. R. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene. Nat. Genet. 1995; 11: 90–92
   PubMed Web of Science ®Google Scholar
• Serra E., Puig S., Otero D., Gaona A., Kruyer H., Ars E., Estivill X., Lazaro C. Confirmation of a double-hit model for the NF1 gene in benign neurofibromas. Am. J. Hum. Genet. 1997; 61: 512–519
   PubMed Web of Science ®Google Scholar
• Serra E., Rosenbaum T., Nadal M., Winner U., Ars E., Estivill X., Lazaro C. Mitotic recombination effects homozygosity for NF1 germline mutations in neurofibromas. Nat. Genet. 2001; 28: 294–296
   PubMed Web of Science ®Google Scholar
• Daschner K., Assum G., Eisenbarth I., Krone W., Hoffmeyer S., Wortmann S., Heymer B., Kehrer-Sawatzki H. Clonal origin of tumor cells in a plexiform neurofibroma with LOH in NF1 intron 38 and in dermal neurofibromas without LOH of the NF1 gene. Biochem. Biophys. Res. Commun. 1997; 234: 346–350
   PubMed Web of Science ®Google Scholar
• John A. M., Ruggieri M., Ferner R., Upadhyaya M. A search for evidence of somatic mutations in the NF1 gene. J. Med. Genet. 2000; 37: 44–49
   PubMed Web of Science ®Google Scholar
• Stark M., Assum G., Krone W. Single-cell PCR performed with neurofibroma Schwann cells reveals the presence of both alleles of the neurofibromatosis type 1 (NF1) gene. Hum. Genet. 1995; 96: 619–623
   PubMed Web of Science ®Google Scholar
• Skuse G. R., Kosciolek B. A., Rowley P. T. Molecular genetic analysis of tumors in von Recklinghausen neurofibromatosis: loss of heterozygosity for chromosome 17. Genes Chromosomes Cancer 1989; 1: 36–41
   PubMed Web of Science ®Google Scholar
• Skuse G. R., Kosciolek B. A., Rowley P. T. The neurofibroma in von Recklinghausen neurofibromatosis has a unicellular origin. Am. J. Hum. Genet. 1991; 49: 600–607
   PubMed Web of Science ®Google Scholar
• Menon A. G., Anderson K. M., Riccardi V. M., Chung R. Y., Whaley J. M., Yandell D. W., Farmer G. E., Freiman R. N., Lee J. K., Li F. P., Barker D. F., Ledbetter D. H., Kleider A., Martuza R. L., Gusella J. F., Seizinger B. R. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc. Natl. Acad. Sci. U. S. A. 1990; 87: 5435–5439
   PubMed Web of Science ®Google Scholar
• Sawada S., Florell S., Purandare S. M., Ota M., Stephens K., Viskochil D. Identification of NF1 mutations in both alleles of a dermal neurofibroma. Nat. Genet. 1996; 14: 110–112
   PubMed Web of Science ®Google Scholar
• Mendell J. T., Dietz H. C. When the message goes awry. Disease-producing mutations that influence mRNA content and performance. Cell 2001; 107: 411–414
   PubMed Web of Science ®Google Scholar
• Serra E., Rosenbaum T., Winner U., Aledo R., Ars E., Estivill X., Lenard H. G., Lazaro C. Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations. Hum. Mol. Genet. 2000; 9: 3055–3064
   PubMed Web of Science ®Google Scholar
• Rutkowski J. L., Wu K., Gutmann D. H., Boyer P. J., Legius E. Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1. Hum. Mol. Genet. 2000; 9: 1059–1066
   PubMed Web of Science ®Google Scholar
• Rasmussen S. A., Overman J., Thomson S. A., Colman S. D., Abernathy C. R., Trimpert R. E., Moose R., Virdi G., Roux K., Bauer M., Rojiani A. M., Maria B. L., Muir D., Wallace M. R. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1. Genes Chromosomes Cancer 2000; 28: 425–431
   PubMed Web of Science ®Google Scholar
• Eisenbarth I., Beyer K., Krone W., Assum G. Toward a survey of somatic mutation of the NF1 gene in benign neurofibromas of patients with neurofibromatosis type 1. Am. J. Hum. Genet. 2000; 66: 393–401
   PubMed Web of Science ®Google Scholar
• Kluwe L., Friedrich R. E., Mautner V. F. Allelic loss of the NF1 gene in NF1-associated plexiform neurofibromas. Cancer Genet. Cytogenet. 1999; 113: 65–69
   PubMed Web of Science ®Google Scholar
• Skuse G. R., Cappione A. J., Sowden M., Metheny L. J., Smith H. C. The neurofibromatosis type I messenger RNA undergoes base-modification RNA editing. Nucleic Acids Res. 1996; 24: 478–485
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay D., Anant S., Lee R. M., Kennedy S., Viskochil D., Davidson N. O. C→U editing of neurofibromatosis 1 mRNA occurs in tumors that express both the type II transcript and apobec-1, the catalytic subunit of the apolipoprotein B mRNA-editing enzyme. Am. J. Hum. Genet. 2002; 70: 38–50
   PubMed Web of Science ®Google Scholar
• Jones P. A. DNA methylation errors and cancer. Cancer Res. 1996; 56: 2463–2467
   PubMed Web of Science ®Google Scholar
• Luijten M., Redeker S., van Noesel M. M., Troost D., Westerveld A., Hulsebos T. J. Microsatellite instability and promoter methylation as possible causes of NF1 gene inactivation in neurofibromas. Eur. J. Hum. Genet. 2000; 8: 939–945
   PubMed Web of Science ®Google Scholar
• Horan M. P., Cooper D. N., Upadhyaya M. Hypermethylation of the neurofibromatosis type 1 (NF1) gene promoter is not a common event in the inactivation of the NF1 gene in NF1-specific tumours. Hum. Genet. 2000; 107: 33–39
   PubMed Web of Science ®Google Scholar
• Guha A. Ras activation in astrocytomas and neurofibromas. Can. J. Neurol. Sci. 1998; 25: 267–281
   PubMed Web of Science ®Google Scholar
• Peters N., Waha A., Wellenreuther R., Friedrich R. E., Mautner V. F., Hoffmeyer S., Lenartz D., Schramm J., Wiestler O. D., von Deimling A. Quantitative analysis of NF1 and OMGP gene transcripts in sporadic gliomas, sporadic meningiomas and neurofibromatosis type 1-associated plexiform neurofibromas. Acta Neuropathol. (Berl) 1999; 97: 547–551
   PubMed Web of Science ®Google Scholar
• Guha A., Lau N., Huvar I., Gutmann D., Provias J., Pawson T., Boss G. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors. Oncogene 1996; 12: 507–513
   PubMed Web of Science ®Google Scholar
• Kluwe L., Friedrich R., Mautner V. F. Loss of NF1 allele in Schwann cells but not in fibroblasts derived from an NF1-associated neurofibroma. Genes Chromosomes Cancer 1999; 24: 283–285
   PubMed Web of Science ®Google Scholar
• Sherman L. S., Atit R., Rosenbaum T., Cox A. D., Ratner N. Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts. J. Biol. Chem. 2000; 275: 30740–30745
   PubMed Web of Science ®Google Scholar
• Perry A., Roth K. A., Banerjee R., Fuller C. E., Gutmann D. H. NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors. Am. J. Pathol. 2001; 159: 57–61
   PubMed Web of Science ®Google Scholar
• Sheela S., Riccardi V. M., Ratner N. Angiogenic and invasive properties of neurofibroma Schwann cells. J. Cell Biol. 1990; 111: 645–653
   PubMed Web of Science ®Google Scholar
• Rosenbaum T., Rosenbaum C., Winner U., Muller H. W., Lenard H. G., Hanemann C. O. Long-term culture and characterization of human neurofibroma-derived Schwann cells. J. Neurosci. Res. 2000; 61: 524–532
   PubMed Web of Science ®Google Scholar
• Muir D., Neubauer D., Lim I. T., Yachnis A. T., Wallace M. R. Tumorigenic properties of neurofibromin-deficient neurofibroma Schwann cells. Am. J. Pathol. 2001; 158: 501–513
   PubMed Web of Science ®Google Scholar
• Muir D. Differences in proliferation and invasion by normal, transformed and NF1 Schwann cell cultures are influenced by matrix metalloproteinase expression. Clin. Exp. Metastasis 1995; 13: 303–314
   PubMed Web of Science ®Google Scholar
• Easton D. F., Ponder M. A., Huson S. M., Ponder B. A. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am. J. Hum. Genet. 1993; 53: 305–313
   PubMed Web of Science ®Google Scholar
• Kayes L. M., Schroeder W. T., Marchuk D. A., Collins F. S., Riccardi V. M., Duvic M., Stephens K. The gene for a novel epidermal antigen maps near the neurofibromatosis 1 gene. Genomics 1992; 14: 369–376
   PubMed Web of Science ®Google Scholar
• Dorschner M. O., Sybert V. P., Weaver M., Pletcher B. A., Stephens K. NF1 microdeletion breakpoints are clustered at flanking repetitive sequences. Hum. Mol. Genet. 2000; 9: 35–46
   PubMed Web of Science ®Google Scholar
• Leppig K. A., Kaplan P., Viskochil D., Weaver M., Ortenberg J., Stephens K. Familial neurofibromatosis 1 microdeletions: cosegregation with distinct facial phenotype and early onset of cutaneous neurofibromata. Am. J. Med. Genet. 1997; 73: 197–204
   PubMed Web of Science ®Google Scholar
• Wu B. L., Schneider G. H., Korf B. R. Deletion of the entire NF1 gene causing distinct manifestations in a family. Am. J. Med. Genet. 1997; 69: 98–101
   PubMed Web of Science ®Google Scholar
• Wu B. L., Austin M. A., Schneider G. H., Boles R. G., Korf B. R. Deletion of the entire NF1 gene detected by the FISH: four deletion patients associated with severe manifestations. Am. J. Med. Genet. 1995; 59: 528–535
   PubMed Web of Science ®Google Scholar
• Upadhyaya M., Ruggieri M., Maynard J., Osborn M., Hartog C., Mudd S., Penttinen M., Cordeiro I., Ponder M., Ponder B. A., Krawczak M., Cooper D. N. Gross deletions of the neurofibromatosis type 1 (NF1) gene are predominantly of maternal origin and commonly associated with a learning disability, dysmorphic features and developmental delay. Hum. Genet. 1998; 102: 591–597
   PubMed Web of Science ®Google Scholar
• Tonsgard J. H., Yelavarthi K. K., Cushner S., Short M. P., Lindgren V. Do NF1 gene deletions result in a characteristic phenotype?. Am. J. Med. Genet. 1997; 73: 80–86
   PubMed Web of Science ®Google Scholar
• Lazaro C., Gaona A., Ainsworth P., Tenconi R., Vidaud D., Kruyer H., Ars E., Volpini V., Estivill X. Sex differences in mutational rate and mutational mechanism in the NF1 gene in neurofibromatosis type 1 patients. Hum. Genet. 1996; 98: 696–699
   PubMed Web of Science ®Google Scholar
• Fang L. J., Vidaud D., Vidaud M., Thirion J. P. Identification and characterization of four novel large deletions in the human neurofibromatosis type 1 (NF1) gene. Human Mutat. 2001; 18: 549–550
   PubMedGoogle Scholar
• Lopez Correa C., Brems H., Lazaro C., Estivill X., Clementi M., Mason S., Rutkowski J. L., Marynen P., Legius E. Molecular studies in 20 submicroscopic neurofibromatosis type 1 gene deletions. Human Mutat. 1999; 14: 387–393
   PubMed Web of Science ®Google Scholar
• Ainsworth P. J., Chakraborty P. K., Weksberg R. Example of somatic mosaicism in a series of de novo neurofibromatosis type 1 cases due to a maternally derived deletion. Human Mutat. 1997; 9: 452–457
   PubMed Web of Science ®Google Scholar
• Cnossen M. H., van der Est M. N., Breuning H., van Asperen C. J., Breslau-Siderius E. J., van der Ploeg A. T., de Goede-Bolder A., van den Ouweland A. M.W., Halley D. J.J., Niermeijer M. F. Deletions spanning the neurofibromatosis type 1 gene: implications for genotype-phenotype correlations in neurofibromatosis type 1?. Human Mutat. 1997; 9: 458–464
   PubMed Web of Science ®Google Scholar
• Jenne D. E., Tinschert S., Stegmann E., Reimann H., Nurnberg P., Horn D., Naumann I., Buske A., Thiel G. A common set of at least 11 functional genes is lost in the majority of NF1 patients with gross deletions [in process citation]. Genomics 2000; 66: 93–97
   PubMed Web of Science ®Google Scholar
• Jenne D. E., Tinschert S., Stegmann E., Reimann H., Nurnberg P., Horn D., Naumann I., Buske A., Thiel G. A common set of at least 11 functional genes is lost in the majority of NF1 patients with gross deletions. Genomics 2000; 66: 93–97
   PubMed Web of Science ®Google Scholar
• Valero M. C., Pascual-Castroviejo I., Velasco E., Moreno F., Hernandez-Chico C. Identification of de novo deletions at the NF1 gene: no preferential paternal origin and phenotypic analysis of patients. Hum. Genet. 1997; 99: 720–726
   PubMed Web of Science ®Google Scholar
• Correa C. L., Brems H., Lazaro C., Marynen P., Legius E. Unequal meiotic crossover: a frequent cause of NF1 microdeletions. Am. J. Hum. Genet. 2000; 66: 1969–1974
   PubMed Web of Science ®Google Scholar
• Stankiewicz P., Lupski J. R. Genome architecture, rearrangements and genomic disorders. Trends Genet. 2002; 18: 74–82
   PubMed Web of Science ®Google Scholar
• Lopez-Correa C., Dorschner M., Brems H., Lazaro C., Clementi M., Upadhyaya M., Dooijes D., Moog U., Kehrer-Sawatzki H., Rutkowski J. L., Fryns J. P., Marynen P., Stephens K., Legius E. Recombination hotspot in NF1 microdeletion patients. Hum. Mol. Genet. 2001; 10: 1387–1392
   Google Scholar
• Tachdjian G., Aboura A., Lapierre J. M., Viguie F. Cytogenetic analysis from DNA by comparative genomic hybridization. Ann. Genet. 2000; 43: 147–154
   PubMedGoogle Scholar
• Mechtersheimer G., Otano-Joos M., Ohl S., Benner A., Lehnert T., Willeke F., Moller P., Otto H. F., Lichter P., Joos S. Analysis of chromosomal imbalances in sporadic and NF1-associated peripheral nerve sheath tumors by comparative genomic hybridization. Genes Chromosomes Cancer 1999; 25: 362–369
   PubMed Web of Science ®Google Scholar
• Schmidt H., Taubert H., Meye A., Wurl P., Bache M., Bartel F., Holzhausen H. J., Hinze R. Gains in chromosomes 7, 8q, 15q and 17q are characteristic changes in malignant but not in benign peripheral nerve sheath tumors from patients with Recklinghausen's disease. Cancer Lett. 2000; 155: 181–190
   PubMed Web of Science ®Google Scholar
• Wallace M. R., Rasmussen S. A., Lim I. T., Gray B. A., Zori R. T., Muir D. Culture of cytogenetically abnormal schwann cells from benign and malignant NF1 tumors. Genes Chromosomes Cancer 2000; 27: 117–123
   PubMed Web of Science ®Google Scholar
• Kehrer H., Krone W. Spontaneous chromosomal aberrations in cell cultures from patients with neurofibromatosis 1. Mutat. Res. 1994; 306: 61–70
   PubMed Web of Science ®Google Scholar
• Glover T. W., Stein C. K., Legius E., Andersen L. B., Brereton A., Johnson S. Molecular and cytogenetic analysis of tumors in von Recklinghausen neurofibromatosis. Genes Chromosomes Cancer 1991; 3: 62–70
   PubMed Web of Science ®Google Scholar
• Ottini L., Esposito D. L., Richetta A., Carlesimo M., Palmirotta R., Ver'i M. C., Battista P., Frati L., Caramia F. G., Calvieri S. Alterations of microsatellites in neurofibromas of von Recklinghausen's disease. Cancer Res. 1995; 55: 5677–5680
   PubMed Web of Science ®Google Scholar
• Fargnoli M. C., Chimenti S., Peris K. Multiple microsatellite alterations on chromosome 9 in neurofibromas of NF-1 patients. J. Invest. Dermatol. 1997; 108: 812–813
   PubMed Web of Science ®Google Scholar
• Birindelli S., Perrone F., Oggionni M., Lavarino C., Pasini B., Vergani B., Ranzani G. N., Pierotti M. A., Pilotti S. Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Lab. Invest. 2001; 81: 833–844
   PubMed Web of Science ®Google Scholar
• Shibata D., Navidi W., Salovaara R., Li Z. H., Aaltonen L. A. Somatic microsatellite mutations as molecular tumor clocks. Nat. Med. 1996; 2: 676–681
   PubMed Web of Science ®Google Scholar
• Legius E., Marchuk D. A., Collins F. S., Glover T. W. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat. Genet. 1993; 3: 122–126
   PubMed Web of Science ®Google Scholar
• Lothe R. A., Slettan A., Saeter G., Brogger A., Borresen A. L., Nesland J. M. Alterations at chromosome 17 loci in peripheral nerve sheath tumors. J. Neuropathol. Exp. Neurol. 1995; 54: 65–73
   PubMed Web of Science ®Google Scholar
• Plaat B. E., Molenaar W. M., Mastik M. F., Hoekstra H. J., te Meerman G. J., van den Berg E. Computer-assisted cytogenetic analysis of 51 malignant peripheral-nerve-sheath tumors: sporadic vs. neurofibromatosis-type-1-associated malignant schwannomas. Int. J. Cancer 1999; 83: 171–178
   PubMed Web of Science ®Google Scholar
• DeClue J. E., Papageorge A. G., Fletcher J. A., Diehl S. R., Ratner N., Vass W. C., Lowy D. R. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 1992; 69: 265–273
   PubMed Web of Science ®Google Scholar
• Basu T. N., Gutmann D. H., Fletcher J. A., Glover T. W., Collins F. S., Downward J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992; 356: 713–715
   PubMed Web of Science ®Google Scholar
• Wu R., Lopez-Correa C., Rutkowski J. L., Baumbach L. L., Glover T. W., Legius E. Germline mutations in NF1 patients with malignancies. Genes Chromosomes Cancer 1999; 26: 376–380
   PubMed Web of Science ®Google Scholar
• Wang Q., Lasset C., Desseigne F., Frappaz D., Bergeron C., Navarro C., Ruano E., Puisieux A. Neurofibromatosis and early onset of cancers in hMLH1-deficient children. Cancer Res. 1999; 59: 294–297
   PubMed Web of Science ®Google Scholar
• Ricciardone M. D., Ozcelik T., Cevher B., Ozdag H., Tuncer M., Gurgey A., Uzunalimoglu O., Cetinkaya H., Tanyeli A., Erken E., Ozturk M. Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1. Cancer Res. 1999; 59: 290–293
   PubMed Web of Science ®Google Scholar
• Boland C. R.
   Google Scholar
• Lothe R. A., Karhu R., Mandahl N., Mertens F., Saeter G., Heim S., Borresen-Dale A. L., Kallioniemi O. P. Gain of 17q24-qter detected by comparative genomic hybridization in malignant tumors from patients with von Recklinghausen's neurofibromatosis. Cancer Res. 1996; 56: 4778–4781
   PubMed Web of Science ®Google Scholar
• Schmidt H., Wurl P., Taubert H., Meye A., Bache M., Holzhausen H. J., Hinze R. Genomic imbalances of 7p and 17q in malignant peripheral nerve sheath tumors are clinically relevant. Genes Chromosomes Cancer 1999; 25: 205–211
   PubMed Web of Science ®Google Scholar
• Schmidt H., Taubert H., Wurl P., Bache M., Bartel F., Holzhausen H. J., Hinze R. Cytogenetic characterization of six malignant peripheral nerve sheath tumors: comparison of karyotyping and comparative genomic hybridization. Cancer Genet. Cytogenet. 2001; 128: 14–23
   PubMed Web of Science ®Google Scholar
• Mertens F., Dal Cin P., De Wever I., Fletcher C. D., Mandahl N., Mitelman F., Rosai J., Rydholm A., Sciot R., Tallini G., van Den Berghe H., Vanni R., Willen H. Cytogenetic characterization of peripheral nerve sheath tumours: a report of the CHAMP study group. J. Pathol. 2000; 190: 31–38
   PubMed Web of Science ®Google Scholar
• O'Sullivan M. J., Kyriakos M., Zhu X., Wick M. R., Swanson P. E., Dehner L. P., Humphrey P. A., Pfeifer J. D. Malignant peripheral nerve sheath tumors with t(X;18). A pathologic and molecular genetic study. Mod. Path. 2000; 13: 1336–1346
   PubMedGoogle Scholar
• Ladanyi M., Woodruff J. M., Scheithauer B. W., Bridge J. A., Barr F. G., Goldblum J. R., Fisher C., Perez-Atayde A., Dal Cin P., Fletcher C. D., Fletcher J. A. Re: O'Sullivan MJ, Kyriakos M, Zhu X, Wick MR, Swanson PE, Dehner LP, Humphrey PA, Pfeifer JD: malignant peripheral nerve sheath tumors with t(X;18). A pathologic and molecular genetic study. Mod pathol 2000;13:1336–46. Mod. Path. 2001; 14: 733–737
   PubMed Web of Science ®Google Scholar
• Liew M. A., Coffin C. M., Fletcher J. A., Hang M. T., Tanito K., Niimura M., Viskochil D. Peripheral nerve sheath tumors from patients with neurofibromatosis type 1 do not have the chromosomal translocation t(X;18). Pediatr. Dev. Pathol. 2002; 5: 165–169
   PubMed Web of Science ®Google Scholar
• Legius E., Dierick H., Wu R., Hall B. K., Marynen P., Cassiman J. J., Glover T. W. TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosomes Cancer 1994; 10: 250–255
   PubMed Web of Science ®Google Scholar
• Halling K. C., Scheithauer B. W., Halling A. C., Nascimento A. G., Ziesmer S. C., Roche P. C., Wollan P. C. p53 expression in neurofibroma and malignant peripheral nerve sheath tumor. An immunohistochemical study of sporadic and NF1-associated tumors. Am. J. Clin. Pathol. 1996; 106: 282–288
   PubMed Web of Science ®Google Scholar
• Liapis H., Marley E. F., Lin Y., Dehner L. P. p53 and Ki-67 proliferating cell nuclear antigen in benign and malignant peripheral nerve sheath tumors in children. Pediatr. Dev. Pathol. 1999; 2: 377–384
   PubMed Web of Science ®Google Scholar
• Guimaraes D. P., Hainaut P. TP53: a key gene in human cancer. Biochimie 2002; 84: 83–93
   PubMed Web of Science ®Google Scholar
• Kourea H. P., Orlow I., Scheithauer B. W., Cordon-Cardo C., Woodruff J. M. Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. Am. J. Pathol. 1999; 155: 1855–1860
   PubMed Web of Science ®Google Scholar
• Nielsen G. P., Stemmer-Rachamimov A. O., Ino Y., Moller M. B., Rosenberg A. E., Louis D. N. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am. J. Pathol. 1999; 155: 1879–1884
   PubMed Web of Science ®Google Scholar
• Sherr C. J. The INK4a/ARF network in tumour suppression. Nat. Rev., Mol. Cell Biol. 2001; 2: 731–737
   PubMed Web of Science ®Google Scholar
• Li X. J., Wang D. Y., Zhu Y., Guo R. J., Wang X. D., Lubomir K., Mukai K., Sasaki H., Yoshida H., Oka T., Machinami R., Shinmura K., Tanaka M., Sugimura H. Mxi1 mutations in human neurofibrosarcomas. Jpn. J. Cancer Res. 1999; 90: 740–746
   PubMedGoogle Scholar
• Foley K. P., Eisenman R. N. Two MAD tails: what the recent knockouts of Mad1 and Mxi1 tell us about the MYC/MAX/MAD network. Biochim. Biophys. Acta 1999; 1423: M37–M47
   PubMed Web of Science ®Google Scholar
• Schreiber-Agus N., Meng Y., Hoang T., Hou H., Jr., Chen K., Greenberg R., Cordon-Cardo C., Lee H. W., DePinho R. A. Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth. Nature 1998; 393: 483–487
   PubMed Web of Science ®Google Scholar
• Serrano M., Gomez-Lahoz E., DePinho R. A., Beach D., Bar-Sagi D. Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science 1995; 267: 249–252
   PubMed Web of Science ®Google Scholar
• Pomerantz J., Schreiber-Agus N., Liegeois N. J., Silverman A., Alland L., Chin L., Potes J., Chen K., Orlow I., Lee H. W., Cordon-Cardo C., DePinho R. A. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92: 713–723
   PubMed Web of Science ®Google Scholar
• Kindblom L. G., Ahlden M., Meis-Kindblom J. M., Stenman G. Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours. Virchows Arch. 1995; 427: 19–26
   PubMed Web of Science ®Google Scholar
• Mulvihill J. J. Malignancy: epidemiologically associated cancers. The Neurofibromatoses: A pathogenetic and Clinical Overview1st Ed., S. M. Huson, R. A.C. Hughes. Chapman & Hall Medical, London 1994; 487
   Google Scholar
• Koch C. A., Vortmeyer A. O., Huang S. C., Alesci S., Zhuang Z., Pacak K. Genetic aspects of pheochromocytoma. Endocr. Regul. 2001; 35: 43–52
   PubMedGoogle Scholar
• Listernick R., Charrow J., Gutmann D. H. Intracranial gliomas in neurofibromatosis type 1. Am. J. Med. Genet. 1999; 89: 38–44
   PubMed Web of Science ®Google Scholar
• Gutmann D. H., Gurney J. G. Other malignancies. Neurofibromatosis. Phenotype, Natural History, and Pathogenesis, J. M. Friedman, D. H. Butmann, M. MacCollin, V. M. Riccardi. The Johns Hopkins University Press, Baltimore 1999; 231–249
   Google Scholar
• Kluwe L., Hagel C., Tatagiba M., Thomas S., Stavrou D., Ostertag H., von Deimling A., Mautner V. F. Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astrocytomas. J. Neuropathol. Exp. Neurol. 2001; 60: 917–920
   PubMed Web of Science ®Google Scholar
• Shannon K. M., O'Connell P., Martin G. A., Paderanga D., Olson K., Dinndorf P., McCormick F. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N. Engl. J. Med. 1994; 330: 597–601
   PubMed Web of Science ®Google Scholar
• Matsui I., Tanimura M., Kobayashi N., Sawada T., Nagahara N., Akatsuka J. Neurofibromatosis type 1 and childhood cancer. Cancer 1993; 72: 2746–2754
   PubMed Web of Science ®Google Scholar
• Maris J. M., Wiersma S. R., Mahgoub N., Thompson P., Geyer R. J., Hurwitz C. G.H., Lange B. J., Shannon K. M. Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1. Cancer 1997; 79: 1438–1446
   PubMed Web of Science ®Google Scholar
• Mahgoub N., Taylor B. R., Le Beau M. M., Gratiot M., Carlson K. M., Atwater S. K., Jacks T., Shannon K. M. Myeloid malignancies induced by alkylating agents in Nf1 mice. Blood 1999; 93: 3617–3623
   PubMed Web of Science ®Google Scholar
• Korf B. R. Malignancy in neurofibromatosis type 1. Oncologist 2000; 5: 477–485
   PubMedGoogle Scholar
• Jacks T., Shih T. S., Schmitt E. M., Bronson R. T., Bernards A., Weinberg R. A. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat. Genet. 1994; 7: 353–361
   PubMed Web of Science ®Google Scholar
• Brannan C. I., Perkins A. S., Vogel K. S., Ratner N., Nordlund M. L., Reid S. W., Buchberg A. M., Jenkins N. A., Parada L. F., Copeland N. G. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev. 1994; 8: 1019–1029
   PubMed Web of Science ®Google Scholar
• Tischler A. S., Shih T. S., Williams B. O., Jacks T. Characterization of pheochromocytomas in a mouse strain with a targeted disruptive mutation of the neurofibromatosis gene Nf1. Endocr. Pathol. 1995; 6: 323–335
   PubMed Web of Science ®Google Scholar
• Cichowski K., Shih T. S., Schmitt E., Santiago S., Reilly K., McLaughlin M. E., Bronson R. T., Jacks T. Mouse models of tumor development in neurofibromatosis type 1. Science 1999; 286: 2172–2176
   PubMed Web of Science ®Google Scholar
• Vogel K. S., Klesse L. J., Velasco-Miguel S., Meyers K., Rushing E. J., Parada L. F. Mouse tumor model for neurofibromatosis type 1. Science 1999; 286: 2176–2179
   PubMed Web of Science ®Google Scholar
• Zhu Y., Ghosh P., Charnay P., Burns D. K., Parada L. F. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 2002; 296: 920–922
   PubMed Web of Science ®Google Scholar